Ads
related to: jazz pharmaceuticals- Careers
Join our Mission to Improve
the Lives of Patients.
- Pipeline
Review our Pipeline and
See How We're Changing Treatment.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- About Us
Discover the Unique Approach
That Makes Genmab Different.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Sign Up
Sign Up for Updates, News
and Much More.
- Careers
Search results
Jazz Pharmaceuticals' phase 2b trial for suvecaltamide fails to meet objectives By Investing.com
Investing.com· 59 minutes agoJazz Pharmaceuticals plc (NASDAQ:JAZZ) disclosed top-line results from its Phase 2b clinical trial...
Jazz Dives, Taking Its Biggest Rival With It, On Drug Failure
Investor's Business Daily· 3 hours agoJazz Pharmaceuticals (JAZZ) said a 30 milligram dose of its drug, suvecaltamide, didn't lead to a...
Jazz hits dud note as midphase essential tremor test misses endpoint
FierceBiotech· 4 hours agoJazz Pharmaceuticals hit a bum note Thursday, reporting the failure of a phase 2b essential tremor...
Jazz Pharmaceuticals’ tremor drug fails to meet main goal in mid-stage study
WHTC 1450 Holland· 5 hours ago(Reuters) -Jazz Pharmaceuticals said on Thursday its experimental drug to treat a neurological condition that causes involuntary and rhythmic shaking failed ...
American Trust Sells 187 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
ETF DAILY NEWS· 4 days agoAmerican Trust lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 10.3% in the 4th quarter, according to the company in its ...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of “Moderate Buy” by Analysts
ETF DAILY NEWS· 4 days agoShares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have received a consensus rating of “Moderate Buy” from the fourteen brokerages that ...
Stocks making the biggest moves midday: Gilead Sciences, Accenture, Trump Media, AMD and more
CNBC· 32 minutes agoThese are the stocks posting the largest moves midday.
3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition
InvestorPlace via Yahoo Finance· 6 days agoIf this year’s market volatility has left you reeling, you’re not alone. But, despite the high...
Takeda's seizure drug fails to meet main goal in late-stage studies
Reuters via Yahoo News· 3 days agoDS affects about one in 21,000 people and LGS affects fewer than one in 1,000 people in the United...
Top-of-mind takeaways from TPRM Summit
Compliance Week· 4 days agoTop-of-mind issues addressed at Compliance Week’s Third-Party Risk Management & Oversight Summit, held June 3-4 in Atlanta, included safe deployment of...